Search
Regulatory Story
Company Horizon Discovery Group plc
TIDM HZD
Headline Director/PDMR Shareholding
Released 17:44 15-Mar-2019
Number 0885T17

RNS Number : 0885T
Horizon Discovery Group plc
15 March 2019
 

Horizon Discovery Group plc

15 March 2019

 

 

Horizon Discovery Group plc

Director/PDMR Shareholding

Cambridge, UK, 15 March 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that 70,730 options were granted today over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to Terry Pizzie, CEO, in accordance with the Company's Long Term Incentive Plan.  The options have an exercise price of 1 pence per share and will vest equally on each of the second and third anniversaries of the grant date. 

The options granted are equivalent to 0.047% of the Company's existing issued share capital. 

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Tel: +44 (0) 1223 655 580

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield / Duncan Monteith

Tel: +44 (0) 207 260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: horizon@consilium-comms.com

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Terry Pizzie

2

Reason for the notification

a)

Position/status

Chief Executive Officer - PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

Options over ordinary shares of 1.0 pence each

 
GB00BK8FL363

b)

Nature of the transaction

Grant of Options

c)

Currency

GBP

d)

Price(s) and volume(s)

Exercise Price

No. of shares

£0.01

70,730

 


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

n/a

f)

Date of the transaction

15 March 2019

g)

Place of the transaction

Off market

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDELFFKXFZBBL
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.